Advanced Medical Research

Global Science Publishing

Number 5 (2026), pp. 01–09

Review

Opioid Use in Cancer Pain Management for Older Adults: Efficacy, Safety, and Individualized Treatment

Shuang Zhang [1], Junxi Mou [1], Guan Wang [1,2] and Fang Wang [1,*]

[1] Innovation Center of Nursing Research and Nursing Key Laboratory of Sichuan Province, West China Hospital, Sichuan University/West China School of Nursing, Sichuan University, Chengdu 610041, China

[2] Key Laboratory of Standardization of Chinese Medicine (Chengdu University of Traditional Chinese Medicine), Ministry of Education, Chengdu 610075, China

Received: May 22, 2026; Revised: May 29, 2026; Accepted: June 5, 2026; Published: June 12, 2026

Abstract: As the population ages and the number of long-term cancer survivors increases, cancer pain management in older adults has become a clinically important issue at the intersection of oncology supportive care, palliative medicine, and geriatric medicine. Opioids use in older adults requires careful balancing of analgesic benefit and safety because of age-related organ dysfunction, multimorbidity, polypharmacy, cognitive and functional impairment, and increased fall risk. This review summarizes the clinical features and management challenges of cancer pain in older adults; examines the therapeutic role and limitations of weak opioids; discusses the efficacy advantages and clinical selection of strong opioids; and outlines principles for opioid dose titration, breakthrough pain management, adverse-effect prevention, and individualized management. Current evidence suggests that weak opioids may be appropriate for selected patients with mild to moderate pain or as short-term transitional therapy. Strong opioids can provide more reliable analgesia for moderate to severe cancer pain. Opioids usage should be guided by comprehensive assessment, low starting doses, gradual dose titration, close monitoring, timely opioid rotation. Individualized opioid management may be achieved via patient stratification, individual-characteristic based opioid selection, individualized dose titration and goal-oriented multimodal and multidisciplinary care. Future studies should include older, frail, cognitively impaired, and multimorbid cancer populations to support practical, evidence-based, and individualized opioid treatment pathways.

Keywords: older adults; cancer pain management; opioids; individualized management

1. Introduction

Cancer pain is among the most frequent symptoms experienced by cancer patients and a major determinant of impaired quality of life. A recent systematic review and meta-analysis showed that pain remains common throughout the cancer trajectory, with a substantial proportion of patients experiencing moderate to severe pain [1]. In older adults, assessment and treatment are complicated by the frequent coexistence of tumor-related pain, treatment-related pain, chronic non-cancer pain, atypical or muted pain expression, cognitive impairment, functional dependence, and social vulnerability [2]. Poorly controlled pain can disturb sleep, restrict mobility, impair nutrition, aggravate anxiety and depression, reduce adherence to anticancer therapy, and accelerate functional decline.

The World Health Organization and contemporary oncology guidelines recommend that analgesic treatment be individualized after assessment of pain intensity, pain mechanism, disease stage, comorbidities, and patient-centered therapeutic goals [3]. For moderate to severe pain caused by cancer or cancer treatment, opioids remain one of the most important treatment options when no contraindication is present [4]. Persistent pain, breakthrough pain, bone metastasis-related pain, and treatment-related pain often require an integrated strategy that combines appropriate opioid formulations, adjuvant analgesics, disease-directed therapy, and, when indicated, nonpharmacological or interventional approaches [5,6].

Compared with opioid therapy in the general adult cancer population, opioid use in older adults requires a more refined approach. Older adults may be particularly vulnerable to inaccurate pain assessment and undertreatment with opioids. Moreover, age-related pharmacokinetic and pharmacodynamic changes, polypharmacy, renal impairment, susceptibility to delirium, and fall risk make analgesic selection and dose titration more complex, necessitating individualized opioid selection, cautious dose titration, and ongoing reassessment to achieve effective pain relief while minimizing adverse effects [7]. This review discusses the current use, efficacy, safety, and individualized opioid treatment for older adults, with the aim of providing a practical reference for clinical care and future research.

2. Characteristics and Management Challenges of Cancer Pain in Older Adults

2.1. Complex Pain Sources and Difficulty in Assessment

Cancer pain in older adults may arise from tumor invasion, bone metastasis, treatment-related injury, neuropathic mechanisms, and chronic inflammatory or visceral processes. Many patients also live with non-cancer pain conditions, such as osteoarthritis, postherpetic neuralgia, diabetic peripheral neuropathy, or pressure injury-related pain. These overlapping sources can obscure the dominant pain mechanism and may lead to either undertreatment of cancer-related pain or excessive reliance on opioids when a non-opioid, adjuvant, rehabilitative, or disease-directed intervention would be more appropriate [8]. Pain assessment should therefore extend beyond a single numeric score and should include pain location, quality, duration, provoking and relieving factors, functional interference, sleep, emotional distress, and the patient's own treatment goals.

Assessment is especially challenging when cognitive impairment, aphasia, hearing loss, low health literacy, or cultural differences limit symptom reporting. In these circumstances, clinicians should not interpret the absence of a clear verbal complaint as absence of pain. Facial expression, guarding, reduced activity, changes in sleep, agitation, appetite, caregiver observations, and structured behavioral assessment tools can provide additional information [2]. For terminally ill or severely frail patients, pain assessment should also take into account comfort, level of alertness or sedation, respiratory status, and caregiver burden, because the balance between analgesia, wakefulness, and overall care goals may change as the disease progresses [9].

2.2. Age-Related Pharmacokinetic and Pharmacodynamic Changes

Because of situations such as reduced hepatic blood flow, lower glomerular filtration rate, changes in body composition, altered plasma protein binding, and increased blood-brain barrier permeability, aging can modify opioid exposure and response. These changes do not affect all opioids equally, but they can narrow the therapeutic window and make adverse reactions more likely when standard adult regimens are applied without adjustment [10,11]. Morphine and some other opioids produce active metabolites that may accumulate in renal impairment, and increase the risk of somnolence, delirium, myoclonus, and respiratory depression. Fentanyl and buprenorphine are less dependent on renal clearance, but their transdermal formulations can be affected by fever, cachexia, skin condition, and local blood flow [12].

Older adults may also have increased pharmacodynamic sensitivity to the central nervous system effects of opioids. A dose that is appropriate for a younger or fitter adult may cause clinically relevant sedation, postural instability, falls, or altered consciousness in a frail older patient. The clinical response should therefore be assessed dynamically: inadequate analgesia may warrant careful dose titration, whereas emerging sedation, delirium, or functional decline should prompt reassessment of the opioid regimen, renal function, concomitant medications, hydration status, and disease progression. The central principle is not simply to use lower doses, but to titrate carefully toward an individualized balance between pain relief, function, and safety [10].

2.3. Multimorbidity, Polypharmacy, and Differences in Care Goals

Comorbidities, such as chronic kidney disease, chronic obstructive pulmonary disease, cardiovascular or cerebrovascular disease, diabetes, osteoporosis, malnutrition, cognitive impairment may exist in older patients with cancer. Comprehensive geriatric assessment can identify vulnerabilities that routine oncology assessment may miss, including functional impairment, cognitive impairment, nutritional deficits, inadequate social support, fall risk, comorbidity, and polypharmacy[13]. These domains directly influence opioid selection, starting dose, monitoring intensity, and the feasibility of home-based treatment. In addition, opioids should be used cautiously with benzodiazepines, sedative-hypnotics, antipsychotics, alcohol, and other central nervous system depressants because these combinations increase the risk of sedation, depression, falls, and overdose [14].

Care goals also differ across older adults and across stages of illness. Some patients prioritize alertness, mobility, and independence, whereas others with advanced disease may prioritize comfort and rapid relief of suffering. Misconceptions about opioids, fear of addiction, concern that opioid use indicates terminal disease, limited access to care, and variable caregiver support can delay analgesic treatment and reduce adherence [7]. Effective management therefore requires not only drug selection, but also shared decision-making, patient and family education, caregiver support, and regular reassessment of treatment goals.

3. Current Use of Opioids in Older Adults

3.1. Role and Limitations of Weak Opioids

Weak opioids mainly include codeine and tramadol. They have traditionally been used for mild to moderate cancer pain or as transitional options before strong opioid therapy. In older adults suffering cancer pain, this classification should not be equated with a uniformly safer risk profile. Codeine requires CYP2D6-mediated conversion to morphine; poor metabolizers may obtain little analgesia, whereas ultrarapid metabolizers may be exposed to toxicity. Tramadol combines weak opioid receptor agonism with norepinephrine and serotonin reuptake inhibition, which may increase the risk of dizziness, nausea, seizures, hyponatremia, serotonin syndrome, and clinically relevant drug interactions, particularly in patients taking antidepressants or other serotonergic agents [15].

The most appropriate role of weak opioids is in mild cancer pain and carefully selected cases of moderate cancer pain, especially when pain is stable, disease progression is slow, short-term transitional treatment is needed, or the patient is hesitant to start a strong opioid. Their advantages include familiarity and greater acceptance by some patients and clinicians. However, their analgesic potency is limited, and their clinical effect may be unpredictable because of inter-individual variability in metabolism and tolerability. In persistent moderate to severe cancer pain, bone metastasis-related pain, or mixed pain syndromes, weak opioids alone often fail to maintain stable analgesia or adequately reduce breakthrough pain and the need for rescue medication [16].

The analgesic ceiling effect of weak opioids has practical implications. Treatment success should be judged not only by a short-term decrease in pain score, but also by whether the patient achieves acceptable pain relief, improved sleep and mobility, better oral intake, fewer breakthrough pain episodes, and manageable adverse effects. When pain becomes moderate to severe, or when non-opioid analgesics, adjuvant analgesics, and disease-directed therapy do not achieve the treatment goal, further dose escalation of a weak opioid is unlikely to provide proportional additional benefit and may increase toxicity. Current guidelines therefore support selecting analgesics according to pain intensity, pain mechanism, previous response, and overall patient condition, rather than requiring every patient to pass mechanically through a weak-opioid step before receiving a strong opioid [4].

3.2. Efficacy Advantages and Clinical Selection of Strong Opioids

Strong opioids, including morphine, oxycodone, hydromorphone, fentanyl, buprenorphine, and methadone, are central agents for moderate to severe cancer pain. Their clinical role should be understood according to pain intensity, pain stability, prior analgesic response, and patient vulnerability rather than simply as the final step after weak opioids have failed [4]. In this context, strong opioids are relevant not only for severe pain but also for selected patients with moderate pain who require more reliable analgesia than weak opioids can provide.

For moderate cancer pain, randomized evidence suggests that a two-step strategy, or the direct use of low-dose strong opioids, can be a reasonable alternative to the traditional three-step ladder in appropriately selected patients [17,18]. This approach is particularly relevant when pain is persistent, when weak opioids are unlikely to provide adequate control, or when treatment goals require earlier stabilization of background pain and reduction of breakthrough pain. The implication is not that all older adults with moderate pain should immediately receive strong opioids, but that treatment should be individualized rather than determined mechanically by the conventional ladder sequence.

For severe, persistent, or fluctuating cancer pain, the efficacy advantage of strong opioids lies in their ability to provide baseline analgesia that can be titrated, maintained, and reassessed over time. Compared with weak opioids, strong opioids generally provide more reliable reductions in background pain, longer analgesic coverage, better control of nocturnal and activity-related pain, and less reliance on repeated rescue medication when prescribed and monitored appropriately [19].

The clinical usefulness of strong opioids is also supported by flexibility in formulation and dosing. Sustained-release or controlled-release preparations can maintain baseline analgesia for persistent pain, whereas short-acting opioids can be used for breakthrough pain. Unlike weak opioids, most strong opioids do not have a fixed analgesic ceiling within the therapeutic range; in practice, further dose escalation is usually limited by tolerability, organ function, drug interactions, and the patient's goals of care [16,20]. For older adults, appropriate use means neither

avoiding strong opioids because of age nor escalating rapidly to high doses. Rather, pain relief, functional improvement, cognition, bowel function, fall risk, and respiratory safety should be considered together when defining treatment success.

Morphine remains a reference standard in many guidelines because of its evidence base, availability, and low cost, but it should be used cautiously in patients with renal impairment, high delirium risk, or with previous opioid-induced neurotoxicity [21]. Oxycodone and hydromorphone can be useful alternatives, although renal and hepatic function and drug interactions still require attention. Transdermal fentanyl may be useful in patients with dysphagia, poor adherence to oral medication, or stable persistent pain, but it is not appropriate for rapid titration or unstable pain in opioid-naive patients [6]. Buprenorphine may be considered in selected patients with renal impairment, but dose conversion, route of administration, and local availability must be considered [22]. Methadone may be helpful for complex pain because of its additional N-methyl-D-aspartate receptor-related effects, but its variable pharmacokinetics and risk of QT interval prolongation require prescribing and monitoring by experienced clinicians [23].

Randomized and comparative studies indicate that several strong opioids can achieve cancer pain control when appropriately titrated. In practice, the optimal choice is often determined less by absolute analgesic superiority than by renal and hepatic function, formulation needs, previous opioid exposure, adverse-effect profile, cost and availability, patient preference, and feasibility of monitoring [16].

3.3. Principles of Administration, Dose Titration, and Breakthrough Pain Management

In older adults with cancer pain, opioid therapy should be guided by low starting doses, gradual opioid dose titration, frequent assessment, and timely adjustment. For opioid-naive patients who are frail, very old, or have hepatic or renal impairment, the starting dose is usually lower than that used in fit younger adults [10]. A conservative starting dose should not be confused with passive undertreatment. Once therapy is initiated, dose titration should be based on analgesic response, breakthrough pain frequency, sedation, respiratory status, bowel function, and functional outcomes [6].

Persistent cancer pain usually requires scheduled dosing to maintain stable baseline analgesia, whereas breakthrough pain requires an appropriate short-acting rescue medication. The frequency and total amount of rescue medication used over 24 h should be recorded. Frequent breakthrough pain may indicate inadequate baseline opioid dosing, an insufficiently treated pain mechanism, or new disease progression. Because breakthrough cancer pain often peaks rapidly, rescue treatment and reassessment should be individualized according to pain pattern, previous opioid exposure, route of administration, and safety risk [24]. Clinicians should also reassess whether baseline dose titration, opioid rotation, adjuvant analgesics, radiotherapy, interventional procedures, bone-modifying agents, or other disease-directed treatments are needed.

4. Opioid-Related Adverse Reactions and Safety Management

4.1. Constipation, Nausea, Vomiting, and Gastrointestinal Management

Opioid-induced constipation is one of the most common and most underestimated adverse reactions. Older adults often have reduced physical activity, insufficient fluid intake, low dietary fiber intake, weakened abdominal musculature, and exposure to other constipating medications, all of which increase the likelihood of persistent constipation after opioid initiation. Because tolerance to constipation usually does not develop, bowel habits and constipation risk should be assessed when regular opioid therapy is started, and prophylactic laxatives, bowel-promoting measures, and bowel monitoring should be appropriately used [25]. Recent evidence also supports pharmacological prevention and treatment of opioid-induced constipation in selected cancer patients, including the use of naldemedine in appropriate settings [25,26].

Nausea, vomiting, and reduced appetite are common during the early phase of opioid therapy or after dose escalation, and some patients develop tolerance after several days. In older adults, dehydration, electrolyte disturbances, vestibular dysfunction, bowel obstruction, metabolic abnormalities, intracranial disease, medication effects, or anticancer therapy may produce symptoms that mimic opioid-related nausea and vomiting [27]. Clinicians should therefore avoid attributing all gastrointestinal symptoms to opioids without reassessment. Targeted antiemetic therapy, hydration, bowel management, and evaluation for reversible causes may reduce treatment discontinuation and functional decline.

4.2. Sedation, Delirium, Cognitive Changes and Falls Risk

Sedation and cognitive changes that happened in older adults require dynamic monitoring throughout opioid therapy. Mild somnolence may occur early after initiation or dose escalation, while persistent drowsiness, marked inattention, hallucinations, myoclonus, sleep-wake reversal, or acute confusion should prompt clinicians to evaluate for possible opioid accumulation, overly rapid dose titration, worsening renal function, infection, dehydration, metabolic disturbances, or concomitant use of other central nervous system depressants [28]. Management should begin with reassessment of the opioid regimen and reversible contributors, followed when necessary by dose reduction, opioid rotation, hydration, treatment of infection or metabolic abnormalities, and simplification of interacting medications.

Fall risk management should be integrated into the entire course of opioid therapy. Older adults frequently have sarcopenia, osteoporosis, visual impairment, gait instability, nocturia, and environmental hazards. Opioid-related sedation, dizziness, and orthostatic symptoms can further increase the risk of falls, fall-related injuries, and fractures [29]. Prevention should combine medication review with practical interventions, such as night lighting, walking aids, footwear assessment, home safety modification, caregiver reminders, and rehabilitation or balance training when feasible.

4.3. Respiratory Depression, Drug Interactions, and Risk Mitigation

Respiratory depression is among the most serious but potentially preventable adverse events of opioid therapy. Risk is higher in older adults with chronic lung disease, sleep apnea, brain lesions, hepatic or renal impairment, frailty, infection, dehydration, or concurrent exposure to benzodiazepines, sedative-hypnotics, antipsychotics, alcohol, or other central nervous system depressants [30]. Observational data show increased overdose risk with opioid-sedative combinations, and studies in older adults with chronic obstructive pulmonary disease support particular caution with opioid-benzodiazepine exposure [31]. The highest-risk periods include treatment initiation, rapid dose escalation, opioid rotation, and acute changes in renal function, hydration, or respiratory status.

Safety management should not rely solely on prescribing fewer opioids. A more effective approach is to establish systematic risk-mitigation practices, including medication reconciliation, avoidance of unnecessary sedative combinations, assessment of renal and hepatic function, standardized opioid conversion, prevention of constipation and nausea, patient and family education, clear instructions on when to seek medical care, and a naloxone rescue plan when appropriate. Recent palliative-care literature also emphasizes the role of pharmacists, palliative-care clinicians, and multidisciplinary collaboration in improving opioid safety for older adults [32].

5. Individualized Management Strategies for Opioid Therapy in Older Adults with Cancer Pain

5.1. Patient Stratification

Individualized opioid therapy in older adults should begin with stratification of patient characteristics rather than selection of a specific drug. Patients differ substantially in physiological reserve, cognitive function, comorbidity burden, organ function, social support, and treatment goals. Consequently, two patients with similar pain intensity scores may require very different opioid management strategies.

Key factors that should guide treatment decisions include pain mechanism, renal and hepatic function, cognitive status, frailty, fall risk, concomitant medications, swallowing ability, caregiver support, expected survival, and patient preferences regarding alertness, mobility, and quality of life. Incorporating geriatric assessment domains into cancer pain management can help identify vulnerabilities that may not be detected through routine oncology assessment alone [13].

From a practical perspective, patients may be broadly categorized into relatively fit older adults, frail older adults, cognitively impaired patients, and patients receiving palliative or end-of-life care. Although these categories often overlap, they provide a useful framework for individualized opioid decision-making.

5.2. Individualized Opioid Selection according to Patient Characteristics

The choice of opioid should be driven by patient-specific characteristics rather than by a uniform treatment algorithm. For example, morphine remains an effective and widely available option for many patients but may be less suitable in the presence of significant renal dysfunction because of active metabolite accumulation [12]. In contrast, fentanyl or buprenorphine may be preferred in selected patients with impaired renal function, provided that formulation-specific limitations are considered.

Transdermal formulations may be useful for selected patients with stable cancer pain when oral administration is difficult or poorly tolerated. However, because transdermal systems are less suitable for rapid

dose titration, rapidly changing pain patterns often require agents and routes that permit easier dose adjustment [33]. Methadone may be useful in selected patients with complex pain syndromes, but its variable pharmacokinetics and potential for QT prolongation generally necessitate specialist oversight [34].

Therefore, individualized opioid selection should be viewed as a process of matching drug characteristics to patient characteristics, rather than identifying a universally superior opioid.

5.3. Individualized Dose Titration

Individualization does not end after opioid initiation. The effective opioid dose varies considerably among older adults because of differences in pharmacokinetics, pharmacodynamics, organ function, and treatment goals.

For relatively fit patients with uncontrolled pain, dose titration may appropriately prioritize analgesic efficacy. In frail patients or those with cognitive impairment, preservation of function and avoidance of delirium may become as important as further pain-score reduction [28]. In patients with high baseline fall risk, maintenance of mobility and fall prevention should also influence the pace and target of dose titration [29]. Consequently, the same degree of residual pain may be acceptable in one patient but not in another. Dose titration should therefore be guided not only by pain intensity but also by functional outcomes, breakthrough pain frequency, sedation, cognition, bowel function, respiratory status, and patient-reported quality of life. The concept of individualized treatment implies continuous adjustment of therapy in response to changing clinical circumstances rather than pursuit of a fixed analgesic target.

5.4. Goal-Oriented Multimodal and Multidisciplinary Care

Individualized management also requires alignment of treatment with patient-centered goals. Some patients prioritize maximal pain relief, whereas others may prioritize alertness, independence, communication with family members, or avoidance of adverse effects. These priorities may evolve throughout the disease trajectory and should be reassessed regularly.

Accordingly, opioid therapy should be integrated with multimodal pain management strategies whenever appropriate. Depending on the underlying pain mechanism, management strategies may include radiotherapy, bone-modifying agents, interventional procedures, anticonvulsants, antidepressants, rehabilitation interventions, psychological support, and caregiver education [6].

Multidisciplinary collaboration further enhances individualization. Pharmacists can contribute to individualized opioid management through medication reconciliation, opioid conversion, identification of drug interactions, and implementation of risk-mitigation strategies [32]. Multidisciplinary cancer pain management models emphasize that effective analgesia requires coordination among oncology, pain medicine, palliative care, nursing, rehabilitation, nutrition, and psychosocial support services rather than reliance on opioid prescribing alone [35]. Recent evidence further suggests that multimodal interprofessional approaches may improve pain control, symptom management, and patient-centered outcomes by integrating pharmacological and non-pharmacological interventions within a coordinated care framework [36]. Through this integrated approach, individualized management moves beyond opioid prescribing alone and becomes a process of tailoring treatment to the needs, vulnerabilities, and priorities of each patient.

6. Limitations of Existing Evidence and Future Directions

6.1. Insufficient Current Evidence

Although the evidence base for opioid therapy in cancer pain is substantial, high-quality studies specifically focused on older adults remain limited. Evidence is particularly sparse for very old, frail, cognitively impaired, multimorbid, and renally impaired patients, even though these populations commonly require cancer pain management in routine practice. Older adults are frequently underrepresented or excluded from cancer-related pain trials, limiting the direct applicability of trial findings to real-world geriatric oncology populations [37].

Existing studies also vary considerably in pain assessment tools, follow-up duration, outcome definitions, adverse-event reporting, and control of concomitant treatments. Many studies focus primarily on pain score reduction, whereas functional status, quality of life, delirium, falls, constipation burden, caregiver burden, and patient preferences are less consistently measured. For older adults, these outcomes may determine whether analgesic treatment is truly appropriate and meaningful.

6.2. Future Research Priorities

Future studies should prioritize large, multicenter, long-term investigations that focus specifically on older adults with cancer pain and clarify the starting doses, dose titration rates, rotation strategies, and long-term safety of different opioids in this population. Study populations should include very old, frail, renally impaired, cognitively impaired, and polypharmacy-exposed patients to improve the relevance of evidence to clinical practice.

Comprehensive outcome measures tailored to geriatric cancer pain management are also needed. The outcomes should include pain relief, breakthrough pain control, sleep, mobility, emotional status, constipation and delirium incidence, fall and fracture risk, caregiver burden, and patient satisfaction. Future work may also integrate pharmacogenomics, pharmacokinetic modeling, electronic pain diaries, and clinical decision support systems to develop individualized dose-prediction and risk-warning tools.

Finally, more research is needed on multidisciplinary clinical pathways and patient education models. Rather than comparing one drug with another in isolation, future studies should evaluate whether integrated pathways that combine standardized assessment, rational prescribing, pharmacist review, nursing follow-up, adverse-reaction prevention, rehabilitation, psychological support, and caregiver education can improve quality of life and medication safety in older adults with cancer pain.

7. Summary

Cancer pain management in older adults is a clinically important issue at the intersection of oncology supportive care, palliative medicine, and geriatric medicine. Opioids remain indispensable for cancer pain management, but their use in older adults requires individualized balancing of analgesic benefit, functional preservation, and safety risk. Weak opioids will still be useful in selected patients with mild to moderate pain or as transitional therapy, but their analgesic ceiling effects, metabolic variability, and drug interactions limit their role in sustained moderate to severe pain. Strong opioids provide more reliable analgesia for moderate to severe cancer pain, provided that dose titration, adverse-reaction prevention, and dynamic monitoring are implemented carefully.

In clinical practice, effective analgesia should not be withheld because of age, but standard adult regimens should not be applied mechanically. A more appropriate approach for older adults includes comprehensive assessment, low starting doses, gradual opioid dose titration, close monitoring, timely opioid rotation, adverse-reaction prevention, multimodal analgesia, patient education, and multidisciplinary collaboration. Future high-quality clinical studies and real-world evidence focusing on older and very old adults with cancer pain are needed to establish more practical opioid treatment pathways for this population.

Funding

This study was supported by the Sichuan Provincial Natural Science Foundation (Grants 2025ZNSFSC0558, 2025ZNSFSC0690), and the Key Laboratory of Geriatric Long-term Care (Naval Medical University), Ministry of Education (Grant. LNZDPY-2025-01 and Grant. LNYB-2025-05), Open Project of Key Laboratory of Standardization of Chinese Medicine (Chengdu University of Traditional Chinese Medicine), Ministry of Education (No. MOECDU2026-04).

Author Contributions

Writing-original draft, S.Z. and J.M.; writing-review and editing, S.Z., F.W. and G.W. All authors have read and agreed to the published version of the manuscript.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

References

1. Snijders RAH, Brom L, Theunissen M, *et al*. Update on Prevalence of Pain in Patients with Cancer 2022: A Systematic Literature Review and Meta-Analysis. *Cancers* 2023; **15**(**3**): 591.
2. Brant JM. Assessment and Management of Cancer Pain in Older Adults: Strategies for Success. *Asia Pacific Journal of Oncology Nursing* 2018; **5**(**3**): 248–253.

3. World Health Organization. *WHO Guidelines for the Pharmacological and Radiotherapeutic Management of Cancer in Adults and Adolescents*; World Health Organization: Geneva, Switzerland, 2018. Available online: https://www.ncbi.nlm.nih.gov/books/NBK537492/ (accessed on 2 June 2026).
4. Paice JA, Bohlke K, Barton D, *et al*. Use of Opioids for Adults with Pain from Cancer or Cancer Treatment: ASCO Guideline. *Journal of Clinical Oncology* 2023; **41**(**4**): 914–930.
5. Fallon M, Giusti R, Aielli F, *et al*. Management of Cancer Pain in Adult Patients: ESMO Clinical Practice Guidelines. *Annals of Oncology* 2018; **29**(**Suppl. 4**): iv166–iv191.
6. Swarm RA, Youngwerth JM, Agne JL, *et al*. Adult Cancer Pain, Version 2.2025, NCCN Clinical Practice Guidelines in Oncology. *Journal of the National Comprehensive Cancer Network* 2025; **23**(**7**). https://doi.org/10.6004/jnccn.2025.0032.
7. Hachem GE, Rocha FO, Pepersack T, *et al*. Advances in Pain Management for Older Patients with Cancer. *Ecancermedicalscience* 2019; **13**: 980.
8. Finnerty D, O'Gara A, Buggy DJ. Managing Pain in the Older Cancer Patient. *Current Oncology Reports* 2019; **21**(**11**): 10.
9. Alexander K, Goldberg J, Korc-Grodzicki B. Palliative Care and Symptom Management in Older Patients with Cancer. *Clinics in Geriatric Medicine* 2016, **32(1)**: 45–62.
10. Guerard EJ, Cleary JF. Managing Cancer Pain in Older Adults. *Cancer Journal* 2017; **23**(**4**): 242–245.
11. Prostran M, Vujovic KS, Vuckovic S, *et al*. Pharmacotherapy of Pain in the Older Population: The Place of Opioids. *Frontiers in Aging Neuroscience* 2016; **8**: 144.
12. King S, Forbes K, Hanks GW, *et al*. A Systematic Review of the Use of Opioid Medication for Those with Moderate to Severe Cancer Pain and Renal Impairment: A European Palliative Care Research Collaborative Opioids Project. *Palliative Medicine* 2011; **25**(**5**): 525–552.
13. Dale W, Klepin HD, Williams GR, *et al*. Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Systemic Cancer Therapy: ASCO Guideline Update. *Journal of Clinical Oncology* 2023; **41**(**26**): 429–4312.
14. American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 Updated AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. *Journal of the American Geriatrics Society* 2023; **71**(**7**): 2052–2081.
15. Crews KR, Monte AA, Huddart R, *et al*. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy. *Clinical Pharmacology & Therapeutics* 2021; **110**(**4**): 888–896.
16. Wiffen PJ, Wee B, Derry S, *et al*. Opioids for Cancer Pain—An Overview of Cochrane Reviews. *Cochrane Database of Systematic Reviews* 2017; 7: CD012592.
17. Bandieri E, Romero M, Ripamonti CI, *et al*. Randomized Trial of Low-Dose Morphine Versus Weak Opioids in Moderate Cancer Pain. *Journal of Clinical Oncology* 2016; **34**(**5**): 436–499.
18. Fallon M, Dierberger K, Leng M, *et al*. An International, Open-Label, Randomised Trial Comparing a Two-Step Approach Versus the Standard Three-Step Approach of the WHO Analgesic Ladder in Patients with Cancer. *Annals of Oncology* 2022; **33**(**12**): 1296–1303.
19. Corli O, Floriani I, Roberto A, *et al*. Are Strong Opioids Equally Effective and Safe in the Treatment of Chronic Cancer? A Multicenter Randomized Phase IV 'Real Life' Trial. *Annals of Oncology* 2016; **27**(**6**): 1107–1115.
20. Caraceni A, Hanks G, Kaasa S, *et al*. Use of Opioid Analgesics in the Treatment of Cancer Pain: Evidence-Based Recommendations from the EAPC. *The Lancet Oncology* 2012; **13**(**2**): e58–e68.
21. Dean M. Opioids in Renal Failure and Dialysis Patients. *Journal of Pain and Symptom Management* 2004; **28**(**5**): 497–504.
22. Melilli G, Samolsky Dekel BG, Frenquelli C, *et al*. Transdermal Opioids for Cancer Pain Control in Patients with Renal Impairment. *Journal of Opioid Management* 2014; **10**(**2**): 85–93.
23. Mercadante S, Bruera E. Methadone as a First-Line Opioid in Cancer Pain Management: A Systematic Review. *Journal of Pain and Symptom Management* 2018; **55**(**3**): 998–1003.
24. Daeninck P, Gagnon B, Gallagher R, *et al*. Canadian Recommendations for the Management of Breakthrough Cancer Pain. *Current Oncology* 2016; **23**(**2**): 96–108.
25. Kistemaker KRJ, Sijani F, Brinkman DJ, *et al*. Pharmacological Prevention and Treatment of Opioid-Induced Constipation in Cancer Patients: A Systematic Review and Meta-Analysis. *Cancer Treatment Reviews* 2024; **125**: 102704.
26. Hamano J, Higashibata T, Kessoku T, *et al*. Naldemedine for Opioid-Induced Constipation in Patients with Cancer: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial. *Journal of Clinical Oncology* 2024; **42**(**35**): 4206–4217.
27. Wickham RJ. Nausea and Vomiting: A Palliative Care Imperative. *Current Oncology Reports* 2020; **22**(**1**): 1.
28. Rekatsina M, Paladini A, Viswanath O, *et al*. Opioids in the Elderly Patients with Cognitive Impairment: A Narrative Review. *Pain and Therapy* 2022; **11**(**2**): 381–394.

29. Yoshikawa A, Ramirez G, Smith ML, *et al*. Opioid Use and the Risk of Falls, Fall Injuries and Fractures among Older Adults: A Systematic Review and Meta-Analysis. *The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences* 2020; **75**(**10**): 1989–1995.
30. Baillargeon J, Singh G, Kuo YF, *et al*. Association of Opioid and Benzodiazepine Use with Adverse Respiratory Events in Older Adults with Chronic Obstructive Pulmonary Disease. *Annals of the American Thoracic Society* 2019; **16**(**10**): 1245–1251.
31. Cho J, Spence MM, Niu F, *et al*. Risk of Overdose with Exposure to Prescription Opioids, Benzodiazepines, and Non-Benzodiazepine Sedative-Hypnotics in Adults: A Retrospective Cohort Study. *Journal of General Internal Medicine* 2020; **35**(**3**): 696–703.
32. Mohammad I, Garwood CL, Binns-Emerick L. A Narrative Review of Risk Mitigation Strategies in the Management of Opioids for Chronic Pain and Palliative Care in Older Adults: Interprofessional Collaboration with the Pharmacist. *Annals of Palliative Medicine* 2024; **13**(**4**): 901–913.
33. Ripamonti C, Fagnoni E, Campa T, *et al*. Is the Use of Transdermal Fentanyl Inappropriate According to the WHO Guidelines and the EAPC Recommendations? A Study of Cancer Patients in Italy. *Supportive Care in Cancer* 2006; **14**(**5**): 400–407.
34. van den Beuken-van Everdingen MH, Geurts JW, Patijn J. Prolonged QT Interval by Methadone: Relevance for Daily Practice? A prospective study in patients with cancer and noncancer pain *Journal of Opioid Management* 2013; **9**(**4**): 263–267.
35. Porzio G, Capela A, Giusti R, *et al*. Multidisciplinary Approach, Continuous Care and Opioid Management in Cancer Pain: Case Series and Review of the Literature. *Drugs in Context* 2023; **12**. https://doi.org/10.7573/dic.2022-11-7.
36. Preti K, D'Aoust R, Beeber AS, *et al*. Multimodal Interprofessional Adult Cancer Pain Management: An Integrative Review. *Oncology Nursing Forum* 2024; **52**(**1**): 41–50.
37. Krysa K, Kowalczyk E, Borysowski J, *et al*. Exclusion of Older Adults from Clinical Trials in Cancer-Related Pain. *Frontiers in Medicine* 2022; **9**: 945481.